Intralesional Candida
Warts are often treated with intralesional Candida if not responding to other therapies.
Credit: DermNet NZ
Introduction to Intralesional Candida
Intralesional Candida antigen is a unique and innovative treatment for stubborn warts that don't respond to conventional therapies. Derived from the yeast Candida albicans, this method leverages the body's immune system to combat the virus responsible for warts. Below, I'll provide a detailed explanation of the procedure, its effectiveness, and what to expect during and after the treatment.
What Is Intralesional Candida Antigen?
Immunotherapy: This treatment is classified as immunotherapy, meaning it triggers the body's immune response to fight off the wart virus.
Targeting Warts: Candida antigen draws the body’s immune cells to the wart area, stimulating them to battle the virus. By treating even one wart, other warts may respond, achieving immunity.
Effectiveness: Data shows a response rate of about 70% after 4 treatments.
The Procedure
Selection of Wart: Generally, the largest wart or the one that's been there the longest is chosen for treatment.
Injection: A small insulin needle is used to inject the antigen into the selected wart.
Observation: Post-injection, patients must remain in the office for 5-10 minutes to ensure no adverse reactions occur.
Post-Treatment Experience
Pain: Most people do not experience pain post-injection. If discomfort occurs, it's often due to local swelling and can be managed with over-the-counter pain relievers.
Inflammation: If significant pain persists, oral steroids may be prescribed for a few days to reduce inflammation.
Healing: There's typically no crusting or blistering of the warts; they will gradually shrink on their own.
Follow-up Treatments: Repeated every 4-6 weeks, up to 3-4 treatments may be necessary before the warts' response can be assessed.
Advantages of the Treatment
Systemic Response: The ability to treat one wart and have others respond is a significant benefit, especially for patients with multiple warts.
Minimal Discomfort: The treatment usually involves minimal pain and easy recovery.
High Success Rate: With about 70% of warts responding after a series of treatments, it offers a valuable option for those who have struggled with other therapies.
Conclusion
Intralesional Candida antigen presents a sophisticated yet accessible option for treating resistant warts, harnessing the body's own immune system to combat the underlying virus. Patients can generally expect a simple procedure, minimal discomfort, and a relatively high success rate. As always, consulting with a healthcare provider experienced in this treatment method ensures appropriate evaluation and personalized care.